Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of DWP712 vs Botox for Glabellar Lines
NCT06212960Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Nov 2023
- Primary completion
- Feb 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Clostridium botulinum toxin type A (DWP712) in glabellar lines (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Number of occurrences for grade 3 or higher adverse drug reactions (ADRs) according to CTCAE 5.0 at 12 weeks. Started Nov 2023; status: completed.
02
Drugs
Clostridium botulinum toxin type A (DWP712)
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT06212960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06212960.